Abeona Therapeutics Inc (NASDAQ:ABEO) Shares Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC grew its holdings in Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) by 581.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 503,293 shares of the biopharmaceutical company's stock after buying an additional 429,456 shares during the quarter. Renaissance Technologies LLC owned about 1.23% of Abeona Therapeutics worth $2,134,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of ABEO. Acadian Asset Management LLC purchased a new position in Abeona Therapeutics in the first quarter worth $91,000. Bank of New York Mellon Corp increased its holdings in shares of Abeona Therapeutics by 2.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company's stock valued at $515,000 after purchasing an additional 2,434 shares in the last quarter. Rosalind Advisors Inc. acquired a new stake in shares of Abeona Therapeutics in the second quarter valued at about $7,420,000. Finally, Western Standard LLC lifted its stake in shares of Abeona Therapeutics by 68.5% in the first quarter. Western Standard LLC now owns 1,361,489 shares of the biopharmaceutical company's stock valued at $9,871,000 after purchasing an additional 553,377 shares during the period. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ABEO has been the topic of several recent analyst reports. StockNews.com upgraded shares of Abeona Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, September 10th. HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Abeona Therapeutics in a report on Wednesday, August 14th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $18.00 price objective on shares of Abeona Therapeutics in a report on Friday, September 20th.

Abeona Therapeutics Price Performance

Shares of NASDAQ ABEO traded up $0.15 on Thursday, hitting $6.38. The company's stock had a trading volume of 204,309 shares, compared to its average volume of 459,392. The stock has a 50 day moving average of $5.37 and a 200-day moving average of $5.32. The company has a market capitalization of $261.34 million, a price-to-earnings ratio of -1.97 and a beta of 1.53. Abeona Therapeutics Inc has a 12-month low of $3.05 and a 12-month high of $9.01. The company has a debt-to-equity ratio of 0.22, a current ratio of 7.48 and a quick ratio of 7.48.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last posted its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.42). As a group, research analysts predict that Abeona Therapeutics Inc will post -1.28 EPS for the current year.

Abeona Therapeutics Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.